• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

作者信息

Benderra Marc-Antoine, Aspeslagh Sandrine, Postel-Vinay Sophie, Bigot Ludovic, De Baere Thierry, Loriot Yohann, Lacroix Ludovic, Massard Christophe, Vassal Gilles, André Fabrice, Soria Jean-Charles

机构信息

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France.

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France.

出版信息

J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18.

DOI:10.1016/j.jtho.2015.08.001
PMID:26845121
Abstract
摘要

相似文献

1
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.获得性表皮生长因子受体（EGFR）突变作为MET突变肿瘤中克唑替尼潜在的耐药驱动因素。
J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18.
2
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.一名对克唑替尼产生获得性耐药的ALK（间变性淋巴瘤激酶）阳性肺腺癌患者同时发生EGFR（表皮生长因子受体）和KRAS（V-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物）突变：病例报告
BMC Res Notes. 2013 Nov 26;6:489. doi: 10.1186/1756-0500-6-489.
3
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.通过综合基因组分析检测具有MET、ALK和ROS1基因组改变的克唑替尼敏感型肺腺癌
Clin Lung Cancer. 2015 Sep;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. Epub 2015 Mar 25.
4
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.BIRC6-ALK，一种在ALK断裂分离FISH阴性肺腺癌中的新型融合基因，对克唑替尼有反应。
J Thorac Oncol. 2015 Jun;10(6):e37-9. doi: 10.1097/JTO.0000000000000467.
5
Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.一名患有携带c-MET扩增的肺腺癌患者对克唑替尼完全缓解。
J BUON. 2017 Jan-Feb;22(1):279-280.
6
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.厄洛替尼/克唑替尼联合治疗一名原发性EGFR突变加继发性MET扩增且获得新型克唑替尼耐药突变MET G1108C的肺腺癌患者。
Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324.
7
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.一例携带MET剪接位点突变的肺腺癌患者对克唑替尼的反应
Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7.
8
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.循环肿瘤DNA鉴定出EGFR共扩增是一名晚期MET扩增肺腺癌患者对克唑替尼耐药的机制。
J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9.
9
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.一名从未吸烟的肺腺癌患者，存在MET外显子14突变（D1028N），接受克唑替尼治疗后出现快速部分缓解。
Invest New Drugs. 2016 Jun;34(3):397-8. doi: 10.1007/s10637-016-0332-0. Epub 2016 Feb 18.
10
Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.ALK重排腺癌转化为肉瘤样癌，该腺癌对克唑替尼产生了获得性耐药并接受了后续化疗。
J Thorac Oncol. 2013 Aug;8(8):e75-8. doi: 10.1097/JTO.0b013e318293d96f.

引用本文的文献

1
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.靶向HGF/MET轴在癌症治疗中的应用：耐药性挑战与改进机遇
Front Cell Dev Biol. 2020 May 6;8:152. doi: 10.3389/fcell.2020.00152. eCollection 2020.
2
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.MET 扩增型非小细胞肺癌细胞对 MET 抑制剂卡马替尼获得性耐药。
Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10.
3
The multiple paths towards MET receptor addiction in cancer.
癌症中 MET 受体成瘾的多种途径。
Oncogene. 2018 Jun;37(24):3200-3215. doi: 10.1038/s41388-018-0185-4. Epub 2018 Mar 19.
4
Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.肺癌及相关淋巴结的突变多样性。4例cIIIA-N2期手术切除病例的探索性前瞻性研究。
Pathol Oncol Res. 2019 Jan;25(1):319-325. doi: 10.1007/s12253-017-0352-x. Epub 2017 Nov 6.